Key Highlights

● Net income was $706,000 for the quarter ended June 30, 2026.

● Management concluded there is substantial doubt about continuing as a going concern.

● Cash was $586,000 and the Working Capital Deficit was $53.29 million.

● Convertible notes closed on September 24, 2026 with net proceeds of $8.8 million.

Celularity Inc. (NASDAQ:CELU) presents a contrasting picture in its latest quarterly filing: Net Income in the period alongside a Going Concern warning. The regenerative medicine company reported net income of $706,000 for the three months ended June 30, 2026, yet management concluded there is substantial doubt about its ability to continue as a going concern. Investors may be weighing how new financing could affect its path.

Latest Company Context

The filing describes Celularity as a longevity-focused regenerative and cellular medicine company that develops and manufactures investigational cell therapies derived from the postpartum placenta, and that also operates biobanking under the Lifebank Brand and biomaterials activities. Revenue was $5.43 million in the second quarter, compared with $5.74 million a year earlier, and $9.28 million for six months, compared with $17.16 million. Net income for six months was $1.58 million, versus a net loss of $44.28 million a year earlier. Net income in a company with an accumulated deficit of nearly $990 million should be read carefully. A profit for the period does not remove the substantial doubt about continuing as a going concern, which management and the filing state clearly.

Key Business and index Drivers

Liquidity is the central driver. Cash and cash equivalents were $586,000 at June 30, 2026, down from $6.18 million at December 31, 2025, while cash, equivalents and restricted cash totalled $10.39 million, including $9.81 million of non-current restricted cash. The working capital deficit was $53.29 million and the accumulated deficit was $989.9 million.

On September 24, 2026, the company completed an initial closing of senior secured convertible notes with net proceeds of $8.8 million, part of a broader plan for up to $25.0 million of new investment. The company also received several Nasdaq deficiency notices during 2026, covering market value, minimum bid price and the late filing of this 10-Q. The filing states that Nasdaq confirmed on September 11, 2026 that it regained compliance with the Market Value and bid price requirements.

What Investors Should Watch

Investors may watch several items. The first is whether the company completes more of the planned $25.0 million financing and on what terms, since convertible notes can affect existing shareholders. The second is the cash balance and runway against the working capital deficit. The third is Nasdaq compliance, including timely filings and the minimum bid price. The fourth is revenue trends, as six-month revenue fell sharply. The fifth is progress on clinical or commercial programmes in cell therapy and biobanking, which may influence long-term prospects.

The sustainability of profit, which may depend on non-operating items, is another point to check in the filing. The company's ability to meet future Nasdaq requirements, including minimum bid price and timely reporting, may influence its listing status and access to capital. Investors may also review the terms of the senior secured convertible notes, including interest, conversion pricing and security, because these determine the claim on the company's Assets and the potential dilution to common holders.

Profit on Paper, Liquidity in Doubt

Celularity reports profit for the period but faces liquidity and listing-compliance questions. The next filings may clarify whether new financing stabilises the position. Investors may therefore view upcoming filings as important checkpoints for liquidity, financing terms and compliance with listing standards, all of which remain unresolved according to the latest report. Smaller Nasdaq-listed companies facing deficiency notices often take steps such as financing and share consolidation to maintain compliance.